6 results
8-K/A
CMMB
Chemomab Therapeutics Ltd
14 Apr 21
UNAUDITED PRO FORMA Condensed COMBINED FINANCIAL STATEMENTS
11:50am
such studies are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical
424B3
CMMB
Chemomab Therapeutics Ltd
12 Feb 21
Prospectus supplement
12:05pm
not be indicative of results obtained when such studies are completed. There is typically an extremely high rate of attrition from the failure
S-4/A
CMMB
Chemomab Therapeutics Ltd
10 Feb 21
Registration of securities issued in business combination transactions (amended)
1:19pm
of results obtained when such studies are completed. There is typically an extremely high rate of attrition from the failure of product candidates
S-4
tm4xnk96ce2d dzls3ow
13 Jan 21
Registration of securities issued in business combination transactions
9:30am
- Prev
- 1
- Next